Supriya Lifescience reported its highest-ever annual revenue of Rs 827.9 crore for FY26, marking an 18.9% year-on-year growth. The company achieved a profit of Rs 209.1 crore and declared a dividend of Re 1 per share. Management expressed confidence in reaching the Rs 1,000 crore revenue milestone in the coming year, backed by new product commercialization and enhanced manufacturing capacity.
Supriya Lifescience Posts Record FY26 Revenue and Profit
Revenue grew 18.9% to Rs 827.9 crore while Profit After Tax rose 11.2% to Rs 209.1 crore.
Reader Takeaway: Strong operational growth and new facility commercialization drive performance; monitor upcoming capacity utilization of new blocks.
What just happened
Supriya Lifescience released its annual performance update for FY 2025-26, highlighting record-breaking revenue and EBITDA. The company successfully commercialized its CMO facility in Ambernath and expanded reactor capacity at Lote Parshuram to 932 KLPD. Additionally, the company declared a final dividend of Re 1.00 per share.
Why this matters
The results demonstrate the company's progress in diversifying its product portfolio beyond traditional APIs. The successful commercialization of new products like Lisdexamfetamine and Sevoflurane indicates a shift toward higher-value offerings. Furthermore, a successful USFDA inspection in February 2026 reinforces the company’s standing in regulated global markets.
What changes now
Management has set a clear goal of achieving Rs 1,000 crore in revenue for FY 2026-27. The company's CMO project, which has secured committed volumes for the next decade, serves as a pillar for future revenue stability. Shareholders will now look toward the upcoming Annual General Meeting to approve the dividend and formalize future expansion plans.
Risks to watch
Investors should note that the company faced supply-chain disruptions and raw material price volatility during the fiscal year. Additionally, management cautioned that new manufacturing blocks typically require a three-year window to reach peak utilization, which may exert temporary pressure on profit margins during the ramp-up phase.
What to track next
The primary monitorable is the speed at which the recently commissioned Ambernath facility reaches peak capacity. Additionally, continued progress on the pipeline of CMO/CDMO projects remains critical for the company's long-term growth trajectory.